GMP IPO Watch
DSP Healthcare Fund
Direct Plan · IDCW · DSP Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +1.72% | +3.52% | 231 of 255 |
| 1M | +1.52% | +1.97% | 161 of 255 |
| 3M | +1.96% | -3.45% | 18 of 252 |
| 6M | +16.45% | +2.92% | 15 of 251 |
| YTD | +6.97% | +1.21% | 65 of 255 |
| 1Y | +6.12% | +1.11% | 66 of 232 |
| 2Y | -2.16% | +2.39% | 155 of 187 |
| 3Y | +11.52% | +12.36% | 89 of 142 |
| 5Y | +6.37% | +9.81% | 84 of 102 |
| 7Y | +15.33% | +14.27% | 46 of 84 |
| INCEPTION | +14.43% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.25% | +44.87% | -23.19% | 66% | 26% |
| 6M | +8.46% | +78.03% | -25.63% | 68% | 27% |
| 1Y | +18.09% | +97.11% | -22.26% | 72% | 31% |
| 2Y | +16.22% | +49.84% | -9.23% | 78% | 34% |
| 3Y | +13.83% | +30.52% | +4.34% | 100% | 44% |
| 5Y | +13.94% | +25.71% | +3.30% | 100% | 44% |
| 7Y | +15.05% | +17.14% | +11.99% | 100% | 46% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity92.16%
- Debt0.00%
- Cash6.74%
- Other1.10%
Market Cap Split
- Large Cap24.86%
- Mid Cap16.01%
- Small Cap43.08%
- Others16.05%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 35.30 | 41.75 |
| P/B | 4.73 | 6.19 |
| Price / Sales | 4.84 | 5.96 |
| Price / Cash Flow | 27.83 | 30.98 |
| Dividend Yield (%) | 0.66 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 8.13% | -0.61% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 7.44% | -0.51% |
| Cipla | Pharmaceuticals & Biotechnology | 7.18% | -0.17% |
| TREPS / Reverse Repo Investments | Reverse Repo / TREPS | 6.81% | — |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 6.52% | -0.93% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 6.15% | +0.17% |
| Apollo Hospitals | Equity | 6.07% | -0.40% |
| Globus Medical Inc | Equity | 5.15% | -0.29% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 4.75% | +0.67% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 4.17% | +0.02% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 3.79% | -0.02% |
| Alembic Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.18% | +0.04% |
| Kovai Medical Center Hospital | Equity | 2.83% | +0.03% |
| Pfizer | Pharmaceuticals & Biotechnology | 2.72% | -0.50% |
| Concord Biotech | Pharmaceuticals & Biotechnology | 2.70% | -0.07% |
View all 34 holdings
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 2.36% | -0.04% |
| Vijaya Diagnostic Centre | Equity | 2.36% | -0.08% |
| Indoco Remedies | Pharmaceuticals & Biotechnology | 2.26% | +0.20% |
| Intuitive Surgical Inc | Equity | 1.95% | +0.19% |
| Thyrocare Technologies | Equity | 1.91% | -0.20% |
| Manipal Health Enterprises | Equity | 1.85% | -1.85% |
| Unichem Laboratories | Pharmaceuticals & Biotechnology | 1.64% | +0.00% |
| Syngene International | Equity | 1.35% | +0.04% |
| Nephrocare Health Services | Equity | 1.12% | -0.01% |
| Global X Funds - Global X Genomics & Biotechnology ETF | Foreign Security | 1.10% | +0.12% |
| ICICI Lombard General Insurance | Insurance | 1.02% | +0.03% |
| Aarti Drugs | Pharmaceuticals & Biotechnology | 0.98% | +0.07% |
| Abbott Laboratories | Pharmaceuticals & Biotechnology | 0.80% | -0.07% |
| Eris Lifesciences | Pharmaceuticals & Biotechnology | 0.72% | -0.04% |
| Jupiter Life Line Hospital | Equity | 0.35% | -0.05% |
| Grail Inc | Equity | 0.31% | +0.14% |
| Abbott | Pharmaceuticals & Biotechnology | 0.26% | — |
| Laxmi Dental | Equity | 0.14% | +0.00% |
| Net Receivables/Payables | Net Current Assets | -0.07% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 15.03 | 16.32 | Low Volatility |
| 3Y | 15.68 | 16.10 | Low Volatility |
| 5Y | 15.88 | 15.67 | High Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.08 | -0.32 | Above Average |
| 3Y | 0.40 | -0.45 | Above Average |
| 5Y | 0.12 | 0.29 | Below Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.63 | 0.19 | Above Average |
| 3Y | 1.02 | 1.14 | Below Average |
| 5Y | 0.60 | 0.96 | Below Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.91 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.91 | 0.96 | Good Risk Adjusted Returns |
| 5Y | 0.90 | 0.95 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From DSP Asset Managers Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
DSP World Mining Overseas Equity Omni FoF
Direct Plan · Growth
|
+30.57% | +26.29% | +17.28% | +8.14% |
| DSP Silver ETF | +25.96% | +36.34% | — | +31.49% |
|
DSP Silver ETF Fund of Fund
Direct Plan · IDCW
|
+24.85% | — | — | +54.98% |
|
DSP US Specific Equity Omni FoF
Direct Plan · Growth
|
+21.65% | +27.47% | +17.63% | +17.56% |
|
DSP World Gold Mining Overseas Equity Omni FoF
Direct Plan · IDCW
|
+21.32% | +42.73% | +20.32% | +5.96% |
|
DSP Global Clean Energy Overseas Equity Omni FoF
Direct Plan · Growth
|
+17.43% | +19.84% | +8.83% | +6.79% |
| DSP Gold ETF | +16.97% | +31.00% | — | +26.42% |
|
DSP Gold ETF Fund of Fund
Direct Plan · IDCW
|
+16.95% | — | — | +31.09% |
| DSP Nifty Healthcare ETF | +13.41% | — | — | +15.38% |
|
DSP Nifty Healthcare Index Fund
Direct Plan · Growth
|
+13.39% | — | — | +13.37% |
About This Scheme
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
1.Equity and Equity related Instruments of Pharmaceutical and Healthcare companies / entities: 80% - 100% 2. Other Equity and Equity related Instruments/ Money Market Instruments / InvITs/ Gold ETFs / Silver ETFs / Other Liquid Instruments / Units of Domestic Mutual Funds^: 0% - 20% For detailed asset allocation pattern, please refer to the Scheme Information Document^Any other security as may be permitted by SEBI/ RBI from time to time. Other Liquid instruments includes cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by the SEBI. The scheme may invest in the units of Overnight Fund, Money Market Fund & Liquid Fund (including Liquid ETFs) of Domestic Mutual Fund.
Exit Load
0.50% - Holding period from the date of allotment <= 1 month, Nil - Holding period from the date of allotment > 1 month (as a % of Applicable NAV)
Fund Managers
Mr. Chirag Dagli
Mr. Chirag Dagli - Primary (Equity and Overseas portion)
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.